The European Thoracic Oncology Platform (ETOP) recently completed a disappointing phase 3 trial for mesothelioma treatment.
Phase II of a clinical trial is recruiting mesothelioma patients to test the effectiveness of two immunotherapy medications in combination.
Making Immunotherapy Mainstream An immunotherapy procedure showing promise in the treatment of mesothelioma may soon be covered under Medicare. In August, the Centers for Medicare & Medicaid Services (CMS) approved the use of Chimeric Antigen Receptor, (CAR T-cell), therapy in patients with two specific cancers: non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. CAR T-cell … Continued
The results of a recent Phase 3 clinical trial have led to a disappointing setback for the mesothelioma community: a highly-touted immunotherapy drug has failed to stop the progression of the disease. Researchers involved in the LUME-Meso study, which combined Ofev (nintedanib) with first-line chemotherapy drugs, say the treatment failed to slow the progression of … Continued
An new Phase 1 clinical trial using chimeric antigen receptor (CAR) T-cell therapy to attack pleural mesothelioma tumors shows promise for cancer patients.
A new type of immunogene therapy, also called virotherapy, is the subject of a Phase 3 clinical trial for patients diagnosed with pleural mesothelioma.